| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation
to the consolidated net loss for the years ended December 31, 2025, and 2024 is included at the bottom of the table below.
| | |
Twelve Months Ended
December 31, | |
| Significant segment expenses | |
2025 | | |
2024 | |
| General and administrative (1) | |
$ | 7,778,869 | | |
$ | 5,786,293 | |
| Pre-clinical research | |
| 378,343 | | |
| 1,479,896 | |
| CMC | |
| 1,887,466 | | |
| 1,463,530 | |
| Clinical development (1) | |
| 5,685,715 | | |
| 4,097,521 | |
| Depreciation and amortization | |
| 662,585 | | |
| - | |
| Share based compensation expense | |
| 297,467 | | |
| 649,029 | |
| Impairment expense | |
| 4,162,911 | | |
| - | |
| Other segment items (2) | |
| 3,939 | | |
| 773,693 | |
| Total operating and segment expenses | |
| 20,857,295 | | |
| 14,249,962 | |
| | |
| | | |
| | |
| Reconciliation of net loss | |
| | | |
| | |
| Change in fair value of warrant liabilities | |
| 115,301 | | |
| (77,806 | ) |
| Realized foreign currency translation loss from dissolution of subsidiaries | |
| (7,171 | ) | |
| - | |
| Foreign currency gain/(loss) | |
| 30,376 | | |
| - | |
| Other income | |
| 380,532 | | |
| - | |
| Change in fair value of derivative warrant liability | |
| (416,619 | ) | |
| | |
| Interest and dividends, net | |
| 327,193 | | |
| 423,184 | |
| Segment and consolidated net loss | |
$ | 20,427,683 | | |
$ | 13,904,584 | |
| (1) | includes personnel costs and excludes share-based compensation expense
and impairment expense |
| (2) | includes litigation settlements, loss from sale of assets, and loss on asset write offs |
|